Abstract
Homeobox D 10 (HOXD10) is a tumor suppressor gene (TSG) involved in cell differentiation and morphogenesis. This study investigated its promoter methylation status and protein expression in endometrial cancer (EC). Samples from 62 EC patients (50 endometrioid adenocarcinoma [EA], 12 mucinous endometrial carcinoma [MEC]) and 70 non-cancerous controls were analyzed. HOXD10 promoter methylation was significantly more frequent in cancer samples ($P < 0.001$). Immunohistochemistry (IHC) confirmed protein downregulation in EC ($P < 0.001$), which correlated negatively with methylation status ($P < 0.05$). Notably, MEC samples showed significantly lower HOXD10 expression than EA samples ($P < 0.001$). Treatment with 5-Aza-2-deoxycytidine partially reversed silencing in the Ishikawa cell line. These results suggest that epigenetic silencing of HOXD10 contributes to EC tumorigenesis and that HOXD10 protein levels may serve as a useful biomarker to distinguish EA from MEC.
Introduction
Endometrial carcinoma (EC) is a leading gynecological malignancy. A significant clinical challenge lies in distinguishing between its pathological subtypes, particularly endometrioid adenocarcinoma (EA) and the rarer, more aggressive mucinous endometrial carcinoma (MEC). MEC is often associated with older age and a higher likelihood of lymphatic metastasis, but its histological boundaries with EA can be ambiguous.
This study investigates the role of HOXD10, a master regulator of cell differentiation, in EC. We hypothesized that HOXD10 is epigenetically silenced via promoter hypermethylation, acting as a driver of the disease and providing a potential diagnostic tool to differentiate these subtypes.
Methods
The study utilized a clinical dataset of 132 paraffin-embedded tissue blocks, including 62 cancer cases (50 EA, 12 MEC) and 70 non-cancerous controls (hyperplasia). The role of HOXD10 was validated through several modalities:
- Methylation-Specific PCR (MSP): To determine the methylation status of the HOXD10 promoter in clinical tissue samples.
- Immunohistochemistry (IHC): To visualize and semi-quantitatively score HOXD10 protein expression in tissue sections.
- Cell Line Validation: The Ishikawa (EC) cell line was treated with 5-Aza-2'-deoxycytidine (5-Aza-CdR), a demethylating agent, to observe if gene silencing could be reversed.
- Western Blotting: Used to quantify protein expression changes following 5-Aza-CdR treatment.
Results
HOXD10 Promoter Hypermethylation
MSP analysis revealed that HOXD10 promoter methylation was significantly more frequent in cancer samples (69.4%, 43/62) compared to non-cancerous controls (15.7%, 11/70; $P < 0.0001$). This confirms that epigenetic silencing via hypermethylation is a common event in EC development.
Protein Downregulation and Subtype Specificity
IHC staining confirmed that HOXD10 protein expression was significantly lower in cancer cases ($P < 0.0001$). A striking finding for diagnostics was the difference between subtypes: 0% of MEC samples expressed the HOXD10 protein, whereas 50% of EA samples still showed positive staining ($P = 0.0010$). This suggests that a total lack of HOXD10 protein is a strong indicator of the mucinous subtype.
Reversibility of Silencing
In the Ishikawa cell line, treatment with the demethylating agent 5-Aza-CdR significantly increased HOXD10 protein levels in a dose-dependent manner ($P < 0.01$). This confirms that the downregulation is indeed epigenetic (due to methylation) rather than a permanent genetic mutation, suggesting potential for epigenetic therapies.
Discussion
The findings demonstrate that epigenetic silencing of HOXD10 contributes to the tumorigenesis of EC. While both EA and MEC exhibit high rates of DNA methylation, the significant difference in protein expression levels indicates that HOXD10 may be a valuable biomarker for distinguishing between these two lesions.
The primary limitation of this study is the small sample size for the MEC subtype (n=12). Larger cohorts are required to confirm HOXD10's reliability as a clinical biomarker. Future research should also explore the specific downstream signaling pathways through which HOXD10 exerts its suppressive effects in endometrial tissues.
Summary updated